Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLPGNASDAQ:HCMNASDAQ:NUVLNASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLPGGalapagos$27.42-2.8%$27.23$22.36▼$31.23N/A0.07249,328 shs322,509 shsHCMHUTCHMED$14.84-3.8%$14.64$11.51▼$21.50$2.69B0.52100,170 shs103,843 shsNUVLNuvalent$75.00-0.7%$73.99$55.54▼$113.51$5.42B1.34494,826 shs558,997 shsRAREUltragenyx Pharmaceutical$37.14-0.6%$36.43$29.59▼$60.37$3.53B0.25839,674 shs1.20 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLPGGalapagos-2.83%-4.66%-5.42%+6.20%+6.11%HCMHUTCHMED-3.82%-12.19%+12.25%-1.00%-16.68%NUVLNuvalent-0.70%-4.14%+1.82%-3.80%-3.97%RAREUltragenyx Pharmaceutical-0.56%-0.93%+4.89%-5.21%-0.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGLPGGalapagos0.1938 of 5 stars0.82.00.00.01.30.00.6HCMHUTCHMED1.8325 of 5 stars3.02.00.00.01.30.01.9NUVLNuvalent2.2021 of 5 stars3.52.00.00.01.53.30.0RAREUltragenyx Pharmaceutical4.259 of 5 stars3.53.00.03.82.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLPGGalapagos 1.50Reduce$25.33-7.61% DownsideHCMHUTCHMED 2.00Hold$19.0028.03% UpsideNUVLNuvalent 2.90Moderate Buy$115.5054.00% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$87.00134.25% UpsideCurrent Analyst Ratings BreakdownLatest HCM, RARE, NUVL, and GLPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025RAREUltragenyx PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.005/28/2025RAREUltragenyx PharmaceuticalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/9/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.003/27/2025RAREUltragenyx PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$104.00 ➝ $117.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLPGGalapagos$298.31MN/A$0.71 per share38.87$47.57 per shareN/AHCMHUTCHMED$630.20M4.10$0.28 per share53.72$4.43 per share3.35NUVLNuvalentN/AN/AN/AN/A$14.99 per shareN/ARAREUltragenyx Pharmaceutical$560.23M6.27N/AN/A$2.76 per share13.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0010.16N/AN/AN/AN/A7/29/2025 (Estimated)NUVLNuvalent-$260.76M-$4.39N/AN/AN/AN/A-31.35%-29.27%8/14/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)Latest HCM, RARE, NUVL, and GLPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLPGGalapagosN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLPGGalapagosN/A7.957.86HCMHUTCHMED0.082.832.70NUVLNuvalentN/A14.4814.48RAREUltragenyx PharmaceuticalN/A2.402.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLPGGalapagos32.46%HCMHUTCHMED8.82%NUVLNuvalent97.26%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipGLPGGalapagos2.91%HCMHUTCHMED3.60%NUVLNuvalent10.20%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLPGGalapagos1,310N/AN/AOptionableHCMHUTCHMED1,811174.32 million168.05 millionNot OptionableNUVLNuvalent4071.81 million64.48 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableHCM, RARE, NUVL, and GLPG HeadlinesRecent News About These CompaniesUltragenyx Pharmaceutical Inc. Grants 48,731 Restricted Stock Units to Newly Hired Non-Executive OfficersJune 20 at 4:43 PM | quiverquant.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20 at 4:30 PM | globenewswire.comGuggenheim Reaffirms Buy Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)June 20 at 9:56 AM | marketbeat.comGAMMA Investing LLC Acquires 26,625 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 17, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Assenagon Asset Management S.A.June 15, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Sells 14,701 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 15, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 3.5% - What's Next?June 12, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by SG Americas Securities LLCJune 12, 2025 | marketbeat.comCantor Fitzgerald Estimates RARE FY2026 EarningsJune 12, 2025 | americanbankingnews.comWedge Capital Management L L P NC Buys Shares of 35,695 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 11, 2025 | marketbeat.comAnalysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $88.77June 11, 2025 | americanbankingnews.comResearch Analysts Offer Predictions for RARE FY2026 EarningsJune 10, 2025 | marketbeat.comChina's rare earth exports climb 23% in May ahead of trade talks with the U.S.June 9, 2025 | msn.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 8, 2025 | marketbeat.comUltragenyx Pharmaceutical reports Q1 earningsJune 6, 2025 | pressdemocrat.comUltragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?June 5, 2025 | zacks.comUltragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comMackenzie Financial Corp Acquires 11,825 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 2, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 1, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 1, 2025 | marketbeat.comEquities Analysts Offer Predictions for RARE FY2025 EarningsMay 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsTesla Stock: Why These 2 Downgrades Are Actually a Buy SignalBy Sam Quirke | June 11, 2025View Tesla Stock: Why These 2 Downgrades Are Actually a Buy SignalHCM, RARE, NUVL, and GLPG Company DescriptionsGalapagos NASDAQ:GLPG$27.42 -0.80 (-2.83%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$27.42 0.00 (0.00%) As of 06/20/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.HUTCHMED NASDAQ:HCM$14.84 -0.59 (-3.82%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$14.83 -0.01 (-0.07%) As of 06/20/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Nuvalent NASDAQ:NUVL$75.00 -0.53 (-0.70%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$74.99 -0.01 (-0.01%) As of 06/20/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Ultragenyx Pharmaceutical NASDAQ:RARE$37.14 -0.21 (-0.56%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$37.56 +0.41 (+1.12%) As of 06/20/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
